Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bio-K: Ketamine for Treatment-Resistant Depression
NCT03156504Phase 4Completed
- Sponsor
- Mayo Clinic
- Start
- Jun 2017
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ketamine in major depressive disorder (MDD), bipolar I disorder, Bipolar II disorder (BP-II), sponsored by Mayo Clinic. Started Jun 2017; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)bipolar I disorderBipolar II disorder (BP-II)
Beyond the preview
Go deeper on NCT03156504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03156504.